<DOC>
	<DOCNO>NCT02955602</DOCNO>
	<brief_summary>An 8-week , dose ranging , open label , randomize , Phase 2 study 18-week extension , evaluate safety efficacy MBX-8025 subject Primary Biliary Cholangitis ( PBC ) inadequate response intolerance ursodeoxycholic acid ( UDCA )</brief_summary>
	<brief_title>MBX-8025 Subjects With Primary Biliary Cholangitis ( PBC ) ( 8 Week , Dose Ranging , Open Label , Randomized Phase 2 With Extension )</brief_title>
	<detailed_description>Primary : To evaluate safety efficacy MBX-8025 5 mg , 10 mg , 25 mg 8 week treatment Secondary : To evaluate safety efficacy MBX-8025 5 mg , 10 mg , 25 mg 26 week treatment To evaluate pharmacokinetics ( PK ) MBX-8025 Exploratory : To evaluate effect MBX-8025 bile acid , additional marker inflammation renal function</detailed_description>
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>1 . Must give write informed consent ( sign date ) authorization require local law 2 . 18 75 year old ( inclusive ) 3 . Male female diagnosis PBC , least two follow criterion : History AP ULN least six month Positive AMA titer ( &gt; 1/40 immunofluorescence M2 positive enzyme link immunosorbent assay ( ELISA ) positive PBCspecific antinuclear antibody Documented liver biopsy result consistent PBC 4 . On stable recommend dose UDCA past twelve month intolerant UDCA 5 . AP ≥ 1.67 × ULN 6 . Females reproductive potential must use least one barrier contraceptive second effective birth control method study least 90 day last dose . Male subject sexually active female partner reproductive potential must use barrier contraception female partner must use second effective birth control method study least 90 day last dose 1 . A medical condition , PBC , investigator 's opinion would preclude full participation study confound result ( e.g. , cancer active treatment ) 2 . AST ALT &gt; 3 × ULN 3 . Total bilirubin &gt; 2.0 mg/dL 4 . Autoimmune hepatitis 5 . Primary sclerosing cholangitis 6 . Known history alpha1Antitrypsin deficiency 7 . Known history chronic viral hepatitis HIV infection 8 . Creatine kinase ULN 9 . Serum creatinine ULN 10 . For female , pregnancy breastfeed 11 . Use colchicine , methotrexate , azathioprine , systemic steroid two month precede screen 12 . Current use fibrates simvastatin 13 . Current use obeticholic acid 14 . Current use experimental unapproved treatment PBC 15 . Current use experimental unapproved immunosuppressant 16 . Adverse event lead MBX8025 discontinuation CymaBay 's phase 2 PBC study ( CB802521528 ) 17 . Hepatic decompensation ( e.g. , known history esophageal variceal bleed , ascites , hepatic encephalopathy ) 18 . Acute pancreatitis know history chronic pancreatitis 19 . Any condition ( ) would compromise safety subject ( e.g. , uncontrolled diabetes , uncontrolled hypertension , severe osteoporosis ) compromise quality clinical study ( e.g. , subject drug alcohol abuse ) , judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>PBC</keyword>
	<keyword>Primary Biliary Cholangitis ( PBC )</keyword>
</DOC>